Alexander Drilon
Led the trials of larotrectinib, entrectinib, repotrectinib and selpercatinib that turned rare gene fusions into treatable targets.
Runs MSK's early drug development service. Lead author on the pivotal NTRK-fusion larotrectinib and ROS1/NTRK repotrectinib studies and a leader of the LIBRETTO RET programme.
| Title | Journal | Year |
|---|---|---|
| Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children | New England Journal of Medicine | 2018 |
| Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer | New England Journal of Medicine | 2024 |
Pages like this
not linked directly; found by shared links- ProductZidesamtinib
Shares Repotrectinib, ROS1, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
- ProductPralsetinib
Shares Selpercatinib, RET, Thyroid cancer, Small-molecule kinase inhibitors.
- TrialLIBRETTO-531
Shares Selpercatinib, RET, Thyroid cancer, Small-molecule kinase inhibitors.
- PersonKoichi Goto
Shares Selpercatinib, ROS1, RET, Non-small-cell lung cancer.
- PairingSequence: targeted therapy before immunotherapy in driver-positive NSCLC
Shares Selpercatinib, ROS1, RET, Small-molecule kinase inhibitors.
- PersonDong-Wan Kim
Shares Repotrectinib, ROS1, Non-small-cell lung cancer.
- ProductTaletrectinib
Shares ROS1, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
- TrialLIBRETTO-431
Shares Selpercatinib, RET, Non-small-cell lung cancer.